Fig. 7.

Knockdown of WNT5B inhibits the tumorigenicity of basal-like cancer cells in vivo. RFP-expressed MDA-MB-231 (a) and Bcap-37 (b) cell pellets under visible light. c Fluorescence images of BLBC cells bearing mice under 530 nm laser irradiation at day 14, 22, and 30 for MDA-MB-231 or at day 6, 12, and 18 for Bcap-37 with/without WNT5B-KD. d Ultrasound images of BLBC cells bearing mice under B-type ultrasonic image system at day 14, 22, and 30 for MDA-MB-231 or at day 6, 12, and 18 for Bcap-37 with/without WNT5B-KD. Subcutaneous tumor of MDA-MB-231 (e) and Bcap-37 (f) with/without WNT5B-KD at the experimental endpoint. Tumor volume of MDA-MB-231 (g) and Bcap-37 (h) at the experimental endpoint (*p < 0.05; **p < 0.005). Tumor growth curve of MDA-MB-231 (i) and Bcap-37 (j) (**p < 0.005; ****p < 0.0001). Tumor weight of MDA-MB-231 (k) and Bcap-37 (l) at the experimental endpoint (*p < 0.05; **p < 0.005)